Date clarification: Today is Thursday, July 16, 2026. Abbott’s 2Q26 earnings call is therefore today, not tomorrow. This preview is framed as a pre-results assessment.
Abbott enters 2Q with a relatively straightforward earnings setup: management guided to adjusted EPS of $1.25–$1.31, while the Street expectation is approximately $1.28, or the midpoint of that range. The more consequential question is not a small EPS beat or miss—it is whether the operational data support management’s confidence in a material second-half acceleration.
The stock has already discounted substantial skepticism. ABT closed at $89.29 on July 15, down roughly 28% year-to-date and about 30% below its January high. Investor concern has centered on the large Exact Sciences acquisition, leverage and acquisition-related EPS dilution, as well as whether Abbott can reaccelerate Nutrition, CGM and Diagnostics simultaneously.
A constructive report would likely require Abbott to show that the areas that slowed in 1Q—particularly Nutrition, Diabetes Care and Core Lab Diagnostics—are improving on the timetable management laid out in April.
| Metric | Expectation / guide | Why it matters |
|---|---|---|
| 2Q26 adjusted EPS | $1.25–$1.31 company guidance; Street near $1.28 | A midpoint outcome is likely insufficient without stronger operating commentary. |
| Underlying sales growth | Street expectation cited near 9.9% | Growth must be interpreted carefully because Exact Sciences is now included in comparable-sales reporting. |
| FY26 comparable sales growth | 6.5%–7.5% | The central debate is whether Abbott can maintain this outlook after a soft 1Q underlying trend. |
| FY26 adjusted EPS | $5.38–$5.58 | Includes approximately $0.20 of Exact Sciences-related dilution. |
| 1Q26 adjusted EPS | $1.15, up 6% year over year | Sets up a notably more back-half-weighted earnings profile. |
Abbott’s full-year EPS range implies a strong second half even if 2Q lands within guidance. Thus, investors should focus intensely on the credibility of the operational building blocks rather than the reported headline alone.
Medical Devices remains Abbott’s primary earnings engine. In 1Q, comparable sales rose 8.5%, led by electrophysiology, rhythm management and heart failure. The key issue in 2Q is whether growth moves meaningfully higher as new product launches contribute.
Abbott has begun rolling out its new pulsed-field ablation portfolio, including Volt in the U.S. and TactiFlex Duo in Europe. Management has indicated that it expects EP growth to accelerate as launches broaden.
What investors want to see - EP growth above the 1Q comparable rate of 12.5%. - Evidence that PFA products are supporting share gains, not simply participating in market growth. - Confidence that Abbott can grow faster than the mid-to-high-teens EP market by year-end.
Continuous glucose monitoring sales grew only 7.6% on a comparable basis in 1Q, affected by a difficult comparison and a delayed international tender. Management explicitly forecast a return to double-digit CGM growth in 2Q.
That makes Libre the cleanest near-term operating test in the quarter.
Bullish read: double-digit CGM growth, strong international recovery and sustained commentary around basal-insulin and non-insulin Type 2 expansion opportunities.
Bearish read: another sub-10% growth quarter, continued softness in U.S. prescription trends, or a more cautious view on the timing of reimbursement catalysts.
Structural Heart was softer in the U.S. in 1Q, while international growth remained strong. Investors will look for evidence that management’s commercial changes are stabilizing the domestic franchise and that competitive pressure in mitral interventions is manageable.
Nutrition was Abbott’s largest operational weak point in 1Q, with comparable sales down 7.7%. Management attributed the decline to lower volumes and strategic price reductions implemented in late 2025 to restore volume growth.
The company said early indicators were encouraging, particularly where lower prices had reached consumers, but characterized the recovery as still early.
For 2Q, the market does not necessarily need Nutrition to return fully to growth. It does need clear proof that the decline is moderating.
Watch for: - Sequential improvement in adult nutrition, especially Ensure. - Better volume trends after pricing actions flow through retail inventory. - Commentary on new-product launches and distribution gains. - Whether management still expects a return to growth in the back half.
Nutrition is especially important because it is a self-help story: a tangible improvement would reinforce management’s broader claim that 2026 growth should accelerate through the year.
Diagnostics grew only 1.8% on a comparable basis in 1Q. The composition matters:
The 2Q issue is whether Core Lab’s recovery continues. In 1Q, management said China Core Lab sales were flat after facing double-digit declines through much of 2025 due to volume-based procurement pressure. Abbott expects Core Lab to reach mid-single-digit growth for the full year, with a stronger second half.
What matters most 1. U.S. contract wins and share gains in Core Lab. 2. Whether China remains stable or improves versus Abbott’s expectation for a full-year decline. 3. Whether respiratory testing remains a headwind or becomes largely irrelevant outside the seasonal period. 4. The pace of Cologuard growth and early evidence that Abbott’s commercial and international infrastructure can broaden Exact Sciences’ reach.
Abbott completed the Exact Sciences acquisition on March 23, 2026, adding cancer diagnostics—including Cologuard, Oncotype DX and Cancerguard—to the portfolio. Exact contributed just $96 million of reported 1Q sales because of the late-quarter close, so 2Q will be the first more meaningful quarter for consolidated results.
The transaction changed the investment debate:
Abbott financed the deal primarily with $20 billion of new long-term debt and reported long-term debt of approximately $34.0 billion at the end of 1Q, versus roughly $12.9 billion at year-end 2025.
For this quarter, investors will want clarity on: - Cologuard volume and revenue growth; - integration progress and synergy opportunities; - international-market development plans; - expected interest expense, amortization and cash-flow implications; - management’s priorities for deleveraging and capital allocation.
The likely valuation debate is whether Exact is a strategically compelling growth asset that can accelerate Abbott’s long-term organic profile—or an expensive transaction that masks softness in legacy businesses. A strong 2Q can help settle that debate in Abbott’s favor.
A modest EPS beat could be discounted if it is driven by tax, FX or timing. Conversely, a result near the midpoint could be well received if Abbott demonstrates the expected operational progression:
Management previously guided to approximately 1% favorable FX impact on full-year reported sales, but expected FX to be roughly neutral for 2Q. That should make this a cleaner quarter for assessing underlying growth.
ABT’s 2Q report is best viewed as a credibility test for the 2026 acceleration narrative. The stock’s decline has created a lower bar for sentiment, but investors will demand evidence that the company’s multiple moving parts are improving at once.
The highest-value signals will be Libre growth, Nutrition volume recovery, EP/PFA execution, Core Lab momentum and the first meaningful quarter of Exact Sciences consolidation. If Abbott delivers progress across those areas while maintaining guidance, the report could shift attention from acquisition skepticism toward an improving medium-term growth profile.